Whitehawk Therapeutics Inc
NASDAQ:WHWKBiotechnology
+$0.06 today
- Market cap
- $184.70M
- Beta
- 0.77
- P/E (TTM)
- -2.6
- EPS (TTM)
- -$1.67
Volume 0.28M
Average 0.31M
WHWK Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Whitehawk Therapeutics IncNASDAQ: WHWK
Stock-Based Compensation · Q4 FY2025 · quarter ended Dec 2025
Stock-based compensation growth accelerates
Q4 FY2025 stock-based compensation of $2.39M rose 28.8% year over year, ahead of the -8.9% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 12.1% from the prior quarter. Over 3 fiscal years it compounded at +0.8% a year.
Context
- Stock-based compensation amounted to 138.2% of revenue in FY2025, up 96.5 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +28.8% holds above the trailing-twelve-month pace of -8.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 9.87M USD
- Year-over-year change
- -8.9%
- 4-year CAGR
- +47.1%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.87M | -8.9% |
| FY2024 | 2024-12-31 | 10.84M | -9.3% |
| FY2023 | 2023-12-31 | 11.95M | +24.0% |
| FY2022 | 2022-12-31 | 9.64M | +357.9% |
| FY2021 | 2021-12-31 | 2.11M | — |
Stock-Based Compensation vs competitors
How WHWK compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -8.9% is the 5th highest of 9, against a peer median of -17.0%.
- Stock-based compensation amounts to 138.2% of revenue for WHWK, versus a peer median of 33.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $21.58M USD | -41.5% | +5.1% | — | |
| LTM Mar 2026 | $14.24M USD | -76.6% | -23.8% | — | |
| LTM Mar 2026 | $12.55M USD | -55.6% | -11.3% | 8.0% | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $9.87M USD | -8.9% | +0.8% | 138.2% |
| LTM Mar 2026 | $7.45M USD | -5.5% | -9.2% | 5559.7% | |
| LTM Mar 2026 | CA$6.75M CAD | +101.1% | +21.4% | — | |
| LTM Mar 2026 | $2.41M USD | -6.9% | -9.8% | 33.9% | |
| LTM Mar 2026 | $2.15M USD | -27.0% | +57.6% | — | |
| LTM Mar 2026 | $1.45M USD | +61.5% | +10.9% | — | |
| Peer median (excluding WHWK) | — | -17.0% | -2.0% | 33.9% | |
Competitors are the stored peer set for WHWK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (110.09M) | (60.51M) | (65.77M) | (63.69M) | (20.6M) |
| Depreciation & Amortization | 105K | 159K | 169K | 193K | 79K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.11M | 9.64M | 11.95M | 10.84M | 9.87M |
| Change in Working Capital | 3.96M | (5.04M) | (3.27M) | 3.72M | 1.93M |
| Accounts Receivables | 14.15M | (1.86M) | (3.63M) | (415K) | (1M) |
| Inventory | 0 | (1.86M) | (3.27M) | 1.12M | 170K |
| Accounts Payables | 0 | 0 | 0 | 0 | 3.92M |
| Other Working Capital | (10.19M) | (1.32M) | 3.62M | 3.02M | (1.16M) |
| Other Non-Cash Items | 81.5M | 6.11M | (2.75M) | (10.61M) | (78.77M) |
| Operating Cash Flow | (22.42M) | (49.64M) | (59.66M) | (59.55M) | (97.43M) |
| Capital Expenditures | (46K) | (444K) | (3.97M) | (1.65M) | (552K) |
| Acquisitions (Net) | 25.2M | 0 | 0 | 0 | 101.29M |
| Purchases of Investments | 0 | (145.19M) | (64.44M) | (36.48M) | (148.69M) |
| Sales of Investments | 0 | 12.75M | 151.62M | 63.34M | 59.85M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 25.15M | (132.89M) | 83.21M | 25.2M | 11.89M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 155M | 72.5M | 0 | 130K | 100M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (4.41M) | 0 | 0 | 0 | 0 |
| Other Financing Activities | (8.78M) | 120K | 326K | (16K) | (5.63M) |
| Financing Cash Flow | 141.8M | 72.62M | 326K | 130K | 94.38M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 64K |
| Net Change in Cash | 144.53M | (109.91M) | 23.87M | (34.22M) | 8.9M |
| Free Cash Flow | (22.47M) | (50.08M) | (63.64M) | (61.2M) | (97.99M) |
Whitehawk Therapeutics Inc
NASDAQ:WHWK
Intrinsic Alpha fair value
Locked
Current Price
$3.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.